Comparative Pharmacology
Head-to-head clinical analysis: ALBALON versus NOVAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBALON versus NOVAFED.
ALBALON vs NOVAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.
Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.
1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours; clinically, dosing every 6-8 hours is recommended, with adjustments in renal impairment
Terminal elimination half-life: 4-8 hours (mean 5-6 hours); prolonged in renal impairment (up to 20 hours) and with urinary alkalinization; in patients with normal renal function, steady-state is achieved after 2-3 days of every-6-hour dosing.
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary/fecal elimination (10-15%)
Renal elimination of unchanged drug and metabolites; approximately 60-70% of a dose is excreted in urine as unchanged pseudoephedrine within 24 hours; the remainder is metabolized hepatically and excreted renally; minimal biliary/fecal elimination (<5%).
Category C
Category C
Ophthalmic Antihistamine/Decongestant
Decongestant